Unveiling the Diabetes Treatment Revolution: Mazdutide's Triumph Over Dulaglutide
A groundbreaking phase 3 trial has revealed a potential game-changer in the treatment of type 2 diabetes. Mazdutide, a once-weekly dual glucagon and glucagon-like peptide-1 (GLP-1) receptor agonist, has shown remarkable results in a head-to-head comparison with dulaglutide. This study not only highlights the potential of multi-agonist therapies but also opens up new avenues for comprehensive diabetes management.
The trial, conducted in a Chinese population, enrolled 731 participants with type 2 diabetes who were already taking oral anti-diabetic medications. The participants were randomly assigned to receive either mazdutide 4 mg, mazdutide 6 mg, or dulaglutide 1.5 mg once weekly for 28 weeks. The results were nothing short of impressive, with mazdutide demonstrating superior glycaemic control and weight reduction compared to dulaglutide.
Mazdutide's Superiority in Glycaemic Control
The study found that both doses of mazdutide met the criteria for non-inferiority and showed statistically significant superiority over dulaglutide in reducing HbA1c levels. The mean HbA1c reductions were notably higher with mazdutide 6 mg compared to the 4 mg dose, indicating a dose-response effect. While the absolute differences in HbA1c levels may seem modest (around 0.25–0.30 percentage points), they were consistent and accompanied by additional metabolic benefits.
Weight Loss and Composite Outcomes
The weight loss advantage of mazdutide was particularly striking. Participants receiving mazdutide achieved mean additional weight losses of approximately 4–6% compared to dulaglutide. The higher dose of mazdutide again produced larger effects. Moreover, a clinically relevant composite endpoint of HbA1c below 7.0% alongside at least 5% weight loss was reached by more participants treated with mazdutide, reflecting the dual-agonist mechanism and the growing emphasis on weight management in type 2 diabetes care.
Safety Profile and Tolerability
Mazdutide was generally well-tolerated over the 28-week study period. Gastrointestinal adverse events, most commonly diarrhoea, nausea, and vomiting, were more frequent with mazdutide than with dulaglutide, which is consistent with other incretin-based therapies. However, no serious safety concerns were highlighted in the study.
Putting the Findings in Context
While the trial was conducted in a specific population, the results suggest that mazdutide can deliver greater improvements in glycaemic control and body weight compared to an established GLP-1 receptor agonist. Although longer-term data and broader population studies are needed, the findings point to the potential role of dual-agonist therapies in future diabetes management. However, it's important not to overstate their immediate clinical impact.
A Controversial Takeaway
But here's where it gets controversial: the study's findings may spark debates about the long-term safety and effectiveness of dual-agonist therapies. While the results are promising, more research is needed to fully understand the potential risks and benefits. This invites discussion and encourages further exploration of this innovative treatment approach.
What do you think? Do you agree with the study's findings, or do you have a different perspective? Share your thoughts in the comments below!
Reference:
Guo L et al; DREAMS-2 investigators. Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes. Nature. 2025; DOI:10.1038/s41586-025-10031-z.
